ANGPT2 and lung cancer: Consistently, others have shown in mouse models of breast and lung cancer that inhibition of angiopoietin-2 (Ang2) (which is produced by the activated endothelium) in the post-surgical adjuvant setting improves pericyte coverage of the endothelium and reduces CCR2+ macrophage accumulation within secondary sites, leading to reduced metastatic progression (83).